ONC — Oncolytics Biotech Cashflow Statement
0.000.00%
Last trade - 00:00
- CA$108.60m
- CA$74.12m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -33.1 | -22.5 | -26.3 | -24.8 | -27.8 |
Depreciation | |||||
Non-Cash Items | 14.5 | -0.219 | 4.33 | 0.697 | -2.86 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -1.8 | 0.21 | -0.908 | 0.391 | 1.76 |
Change in Accounts Receivable | |||||
Change in Prepaid Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Change in Other Liabilities | |||||
Net Change in Other Assets & Liabilities | |||||
Cash from Operating Activities | -19.9 | -22.1 | -22.4 | -23.4 | -28.4 |
Capital Expenditures | -0.011 | -0.029 | -0.286 | -0.055 | -0.008 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 0 | — | — | -20.3 | 20.2 |
Sale/Maturity of Investment | |||||
Change in Net Investments | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -0.011 | -0.029 | -0.286 | -20.4 | 20.2 |
Financing Cash Flow Items | 8.13 | 38.3 | 32.9 | 12.6 | 10.3 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 21 | 39.8 | 33 | 12.2 | 32 |
Foreign Exchange Effects | |||||
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 0.448 | 17.1 | 10 | -29.6 | 23.2 |